Article Text

Download PDFPDF
Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy
  1. Jay Ramchand,
  2. Agostina M Fava,
  3. Michael Chetrit,
  4. Milind Y Desai
  1. Heart and Vascular Institute, Cleveland Clinic Miller Family Heart and Vascular Institute, Cleveland, Ohio, USA
  1. Correspondence to Dr Milind Y Desai, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA; desaim2{at}


Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac condition, which typically manifests as left ventricular hypertrophy. A small subset of patients with HCM have an increased risk of sudden cardiac death (SCD) from ventricular arrhythmias. Risk of SCD can be effectively reduced following implantation of implantable cardiac defibrillators (ICD), although this treatment carries a risk of complications such as inappropriate shocks. With this in mind, we turn to advances in cardiac imaging to guide risk stratification for SCD and to select the appropriate individual who may benefit from ICD implantation. In this review, we have taken the opportunity to briefly summarise the role of imaging in the diagnosis of HCM before focusing on how specific imaging features influence risk of SCD in patients with HCM.

  • cardiac magnetic resonance (CMR) imaging
  • echocardiography
  • implanted cardiac defibrillators
  • hypertrophic cardiomyopathy
  • cardiac arrest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @DrJRamchand, @agofava, @ChetritMichael, @DesaiMilindY

  • Contributors JR and MYD took the lead in writing the manuscript. AMF and MC provided critical feedback and helped shape the figures and tables.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MYD is on the steering committee of the Hypertrophic Cardiomyopathy Registry (HCMR) trial sponsored by the National Institutes of Health. MYD also acknowledges Haslam Family Endowed Chair in Cardiovascular Medicine.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles